中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

DC-CIK细胞免疫疗法对原发性肝癌患者免疫功能的影响及临床意义

作者：侯光华 1 郝建军 2 时昭红 2 胡启江 1

单位：1.武汉市黄陂区人民医院内三科武汉 430300 2.武汉市中西医结合医院消化内科武汉 430022

关键词：原发性肝癌树突状细胞细胞因子免疫功能

分类号：

出版年,卷(期):页码：2016,8(4):82-86

摘要：

摘要：目的探讨树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）免疫疗法对原发性肝癌患者免疫
功能的影响及临床意义。方法随机选取2013年至2015年于武汉市黄陂区人民医院确诊并行肝动脉化
疗栓塞术（TACE）的90例原发性肝癌患者进行前瞻性分析，随机分为治疗组和对照组，治疗组50
例，行肝癌切除术，术后给予DC-CIK细胞治疗；对照组40例，仅行肝癌切除术。治疗结束后统计
两组患者的治疗总有效率、免疫功能、生活质量及不良反应等情况。结果经DC-CIK细胞治疗后，
治疗组患者的CD3 + 、DC 1 /DC 2 、和CD4 + /CD8 + 均升高，与治疗前相比差异有统计学意义（t值分别为
1.64、0.54和0.39，P值分别为0.032、0.038和0.029）。治疗组32%（16/50）的患者生活质得到改善，
显著高于对照组的17.5%（7/40），差异有统计学意义（χ 2 = 12.6，P = 0.045）。治疗组总有效率为
90%（45/50），对照组为72.5%（29/40），差异有统计学意义（χ 2 = 5.70，P = 0.04）。经治疗，治
疗组患者的Th1细胞由（8.5 ± 3.3）%升高至（12.9 ± 4.4）%，Th2细胞由（5.6 ± 2.5）%下降至（4.6 ±
1.7）%，差异有统计学意义（t = 0.025、0.028，P = 0.041、0.039）。结论经DC-CIK细胞免疫治疗
后，原发性肝癌患者的免疫功能显著增强，治疗总有效率较高，且对患者的生存质量有一定的改善。

Abstract: Objective To investigate the clinical effects of dendritic cells-cytokine induced killer cells (DC-
CIK) immunotherapy on immune function in patients with primary liver cancer. Methods Total of 90 patients
with primary liver cancer who underwent TACE from 2013 to 2015 in People’s Hospital of Huangpo District
were randomly selected and divided into treatment group (50 cases) and control group (40 cases). Patients
in treatment group were given hepatectomy and DC-CIK cell therapy and patients in control group were
given hepatectomy only. After treatment, the total effective rate, immune function, quality of life and adverse
reactions were analyzed. Results After treatment, the levels of CD3 + , DC 1 /DC 2 and CD4 + /CD8 + in treatment
group were significantly higher than those in control group (t = 1.64, 0.54, 0.39; P = 0.032, 0.038, 0.029).
In treatment group, the life quality of 32% (16/50) patients improved, which was significantly higher than
that in the control group [17.5% (7/50), χ 2 = 12.6, P = 0.045]. After DK-CIK cell therapy, Th1 in treatment
group increased from (8.5 ± 3.3)% to (12.9 ± 4.4)% and Th2 decreased from (5.6 ± 2.5)% to (4.6 ± 1.7)%,
the differences were statistically significant (t = 0.025, 0.028, P = 0.041, 0.039). Conclusion After DC-CIK
therapy, the immune functionin of patients with primary liver cancer increased significantly, the treatment
efficiency and the life quality also had some improvement.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】